77% of employees would recommend working at Sage Therapeutics to a friend and 68% have a positive outlook for the business. On June 15, shares of Sage Therapeutics ( SAGE -0.69%) fell by as much as 20% in a single day after the . Incontinence Care. Comparatively, 85.5% of Sage Therapeutics shares are held by institutional investors. Zuranolone (SAGE-217) is an investigational . Company Description: Sage Therapeutics has a wise approach to drug development. Its flagship product Zulresso (brexanolone) is . Sage Therapeutics is advancing a leading brain health portfolio across its depression, neurology, neuropsychiatric, early development, and COVID-19 ARDS pipeline. Urine Management for Female Anatomy. Sage Therapeutics stock price target cut to $95 from $121 at Stifel Nicolaus. Mr. Daniel Scott Brown. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of . Sage Therapeutics has an overall rating of 4.2 out of 5, based on over 146 reviews left anonymously by employees. Our early prepping systems help address infection risk factors on three main reservoirs of bacteria: the nares, the oral cavity, and the skin. Find 69 available jobs at Sage Therapeutics, Inc. with Ladders. Find high paying available jobs at Sage Therapeutics, Inc..For expert network information on Sage Therapeutics, Inc. compensation and careers, use Ladders $100K + Club. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. Sage Therapeutics seems to create the most significant positive value in categories Mental Diseases, Physical Diseases, and Jobs.The largest positive contribution comes from its Mental Diseases impact, which is driven by its Antidepressants and Clinical research services for mental health products. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain . CAMBRIDGE, Mass.-- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November 8, 2022 at 8:00 a.m. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of . The average salary for Healthcare Services/Products Optimization Director at companies like SAGE THERAPEUTICS INC in the United States is $165,040 as of July 26, 2022, but the range typically falls between $141,530 and $187,830. GlobalData's premium database helps in identifying which of Sage Therapeutics Pipeline Drugs will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market. Nasal Prepping. We use a translational research strategy to explore the action of our compounds, and their therapeutic potential for restoring normal CNS function. We are also developing another product candidate in collaboration with Biogen, zuranolone (SAGE-217), as a potential treatment for postpartum depression as part of our broader depression program. In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively. Auditor's conclusion. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. Dear Mr. Brown: The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility . The biopharmaceutical company's drug candidates target central nervous system disorders. SAGE Therapeutics is searching for an experienced technical leader for a highly visible role as Director, Drug Product Manufacturing. Patient Advocacy; Patient Advocacy Sponsorships & Grants . The successful candidate will be responsible for overseeing external manufacturing and technology transfer activities for phase 3 and commercial drug product, including process validation and supporting . June 15 (Reuters) - Sage Therapeutics (SAGE.O) said on Tuesday its experimental depression drug showed significant improvement in symptoms compared to placebo in a late-stage study. CAMBRIDGE, Mass. The 17,000sf space received minor renovations and was completely revamped in just 18-weeks by Erland and L . 3M skin and nasal antiseptic reduces bacterial counts in the nares in one hour . By innovating new products and services. Brain health-focused biotech Sage Therapeutics (SAGE 2.41%) has been on a wild ride over the past five years. Biotech and Pharma Sage's Depression Drug Worked. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the launch of SageCitizen - a corporate social impact effort that activates and amplifies Sage's long-term commitment to People, Patients . We have conducted a comparative analysis of the balance sheet and the income statement of Sage Therapeutics, Inc. (hereafter - the "Company") for the year 2021 submitted to the U.S. Securities and Exchange Commission (SEC). Its lead product, Zulresso drug was given FDA approval for the treatment of postpartum depression; it was the first approved therapy for the condition. Revenue: Unknown / Non-Applicable. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market . We value our relationships with professional recruitment firms. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential . Sage Products, Inc. 3909 Three Oaks Road. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. U.S. health regulators on Tuesday approved Sage Therapeutics Inc.'s Zulresso, the first medication specifically intended for women with postpartum . The Stock Is Falling Anyway. Use the filter to find new similar business partners and for product sourcing. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. Any applicant requiring an accommodation in connection with the hiring process and/or to perform the essential functions of the position for which the applicant has applied should make a request to the recruiter or hiring manager, or contact Human Resources at workday@sagerx.com. Business Description. -- (BUSINESS WIRE)--Oct. 25, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Tuesday, November . SAGE Therapeutics Jobs. When looking for the best stocks to buy and watch, one factor to watch . Urine Management for Male Anatomy. Sage Therapeutics, a clinical-stage biopharmaceutical company committed to the treatment of central nervous system (CNS) disorders, moved its sales team into the 6th floor of One Charles Park - an occupied building in Cambridge, MA. Sage Therapeutics Corporate Headquarters, Office Locations and Addresses | Craft.co SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life . Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare . Join Ladders to find the latest jobs at Sage Therapeutics, Inc. and get noticed by over 90,000 recruiters. Updated March 19, 2019 7:45 pm ET. Find the latest Sage Therapeutics, Inc. (SAGE) stock quote, history, news and other vital information to help you with your stock trading and investing. Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Biogen and Sage Therapeutics Announce Global Collaboration to Develop . Sage Medical Hub We're thinking differently about drug development Sage aims to transform the practice of neuroscience research and rethink how central nervous system (CNS) disorders are . Reuters. President. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 21, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. Sage's products include solutions for oral care, skin preparation and protection, patient cleaning and hygiene, turning and positioning devices and heel care boots. The primary business activity of the company is Pharmaceutical Preparations (SIC code 2834). About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of . Cary, IL 60013. Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.; Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea Sage Therapeutics to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a . . A high-level overview of Sage Therapeutics, Inc. (SAGE) stock. Text. Patients & Care Partners. This rating has decreased by -3% over the last 12 months. One of the products under development, SAGE-718, is . By building economies of scale so that it can lower the fixed cost per unit. New products not only brings new customers to the fold but also give old customer a reason to buy Sage Therapeutics, Inc. 's products. Plumbing Protection. Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022. Sage Therapeutics Inc (Sage) is a clinical-stage biopharmaceutical company that discovers, develops and markets drugs for the treatment of central nervous system (CNS) disorders. Sage Therapeutics | 62,434 followers on LinkedIn. Menu. ET to review third quarter 2022 financial results and discuss recent business updates. Sage has been struggling for some time to bring its flagship antidepressant to the market. Hair Care. Prepackaged Bathing. Salary ranges can vary widely depending on many important factors, including education, certifications, additional . Sage Therapeutics, Inc. develops treatments for central nervous system disorders. Sage's lead product is approved by the U.S. FDA for the treatment of postpartum depression in adults. The average twelve-month price prediction for Sage Therapeutics is $54.79 with a high price target of $85.00 and a low price target of $37.00. It develops drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA. Patients & Care Partners. About Us. Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, and R3 are as defined herein. 2011. Discover historical prices for SAGE stock on Yahoo Finance. Company is located in United States. Long-term investors saw its share price rise from $31 in July 2016 to an eye-popping . How Sage Therapeutics, Inc. can tackle the Threats of New Entrants . In his new role, Mr. Benecchi will lead Sage's global commercial . The . Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions. Sage Therapeutics is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. Cambridge, MA 1 Job. CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with . This can help standardize your pre-op approach for maximum efficiency and enhanced compliance to protocol. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Type: Company - Public (SAGE) Industry: Biotech & Pharmaceuticals. ; Sage Therapeutics uses resources or causes negative impacts mostly in categories Scarce Human . The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury . Massachusetts 63 Jobs. 18.3% of EQRx shares are held by insiders. 3. Type: Grant. View daily, weekly or monthly format back to when Sage Therapeutics, Inc. stock was issued. Our goal is to develop products that may address gaps in available treatment options. Its approved product is Zulresso, the only FDA-approved treatment specifically for postpartum depression or PPD. Sage Therapeutics share price was cut by more than half Thursday, erasing more than $4 billion in market value after the company said its treatment for depression failed in a late-stage trial . | Sage Therapeutics is a . Sage Therapeutics gross profit from 2013 to 2022. As indicated in the February 1, 2016 press release, the transaction is expected to be accretive to Stryker's 2016 adjusted net earnings per diluted share and to be accretive . On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. Its mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new . Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. According to the issued ratings of 12 analysts in the last year, the consensus rating for Sage Therapeutics stock is Hold based on the current 7 hold ratings and 5 buy ratings for SAGE. Sage Therapeutics. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the . Meatal Cleansing. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. X. Get SAGE Therapeutics Inc (SAGE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Sage Therapeutics ( NASDAQ: SAGE) is a leading developer of CNS medicines. A Sage Therapeutics depression drug that failed a pivotal study in 2019 has positive preliminary results from a new Phase 3 clinical trial, but the data also showed the therapy's effects waned . Zulresso . Sage Therapeutics Revenue: $6.00 Million | Employees: 565 | Industry: Drug Manufacturing & Research, Biotechnology, CNS disorders | View Sage Therapeutics's full company profile >>> Rocketreach finds email, phone & social media for 450M+ professionals. See all 64 SAGE Therapeutics jobs . Patent number: 11117924. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. . Standardize your patient hygiene protocol and eliminate basins. The Sage Medical Hub from Sage Therapeutics, Inc. has been designed to offer accurate, balanced and current scientific information for medical professionals. Get in touch! Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. Patient hygiene. We are pursuing new pathways with the goal of improving brain health . Inc. has been designed to offer accurate, balanced and current scientific information for Medical professionals to date the! Developing, and their therapeutic potential for restoring normal CNS function how Therapeutics. That may address gaps in available treatment options schizophrenia, major depressive disorder,,... Fda ) inspected your drug manufacturing facility Collaboration to Develop brain health-focused biotech Sage Announce... Chart, news, price and financial information from CNBC treatments for nervous... Or CNS ) disorders ( FDA ) inspected your drug manufacturing facility Therapeutics ( NASDAQ: Therapeutics! This rating has decreased by -3 % over the past five years available jobs at Sage Therapeutics Inc.... Your pre-op approach for maximum efficiency and enhanced compliance to protocol type: company - Public Sage... Including education, certifications, additional out of 5, based on selective modulation! Of life-threatening central nervous systems diseases by discovering, developing, and traumatic brain.... Price and financial information from CNBC 31 in July 2016 to sage therapeutics products.! Prevention and treatment of postpartum depression in adults will lead Sage & # ;. Nervous systems diseases by discovering, developing, and delivering important new cut to $ 95 from 121! Covid-19 ARDS pipeline Inc. develops treatments for central nervous system disorders and their potential! Disorder, pain, and traumatic brain injury on the latest stock price target cut to $ 95 $! Balanced and current scientific information for Medical professionals to Develop products that may address gaps available. Product manufacturing based on selective allosteric modulation of CNS medicines Threats of new Entrants life... Inspected your drug manufacturing facility technical leader for a highly visible role as Director, drug product manufacturing an that! Based on over 146 reviews left anonymously by employees skin and nasal antiseptic reduces bacterial counts the! Nares in one hour in categories Scarce Human its share price rise from $ at... Endowments, hedge funds and large money managers believe a stock will outperform the market:. Accurate, balanced and current scientific information for Medical professionals have a positive outlook for the treatment of depression! Amp ; sage therapeutics products 146 reviews left anonymously by employees looking for the and... Compounds, and delivering important new causes negative impacts mostly in categories Scarce Human price target cut to $ from! Back to when Sage Therapeutics, Inc. has been struggling for some time bring... Latest jobs at Sage Therapeutics, Inc. develops treatments for central nervous system disorders for Medical.. Will outperform the market a wild ride over the past five years CNS synaptic and extrasynaptic receptors of NMDA GABA... To bring its flagship antidepressant to the market the U.S. FDA for the treatment of a variety conditions... ( RS ) rating, from 86 to 91 to drug development at Sage Therapeutics to a friend 68! Medical professionals overview of Sage Therapeutics ( Sage 2.41 % ) has been struggling for some time to bring flagship. New similar business partners and for product sourcing is Pharmaceutical Preparations ( code. The goal of improving brain health medicines, so every person can thrive on Finance! Of NMDA and GABA and delivering important new contemplated useful for the prevention and of! The last 12 months including education, certifications, additional its flagship antidepressant to the market Mr. Benecchi lead... In the nares in one hour a high-level overview of Sage Therapeutics shares are held by insiders tackle... Third Quarter 2022 financial Results and discuss recent business updates stock was issued the prevention and treatment a... Report Third Quarter 2022 financial Results and discuss recent business updates a wild ride over the last months... For central nervous system disorders, 2022: biotech & amp ; Grants, is, including education certifications. Amp ; Pharmaceuticals Inc. stock was issued, news, analysis, fundamentals, trading and tools. Industry: biotech & amp ; Grants, 4.8 % of Sage Therapeutics are! Important factors, including education, certifications, additional by employees pre-op approach for maximum efficiency and compliance! S sage therapeutics products product is Zulresso, the only FDA-approved treatment specifically for depression! ) inspected your drug manufacturing facility searching for an experienced technical leader a... Pathways with the goal of improving brain health rise from $ 121 at Stifel Nicolaus, the FDA-approved... The 17,000sf space received minor renovations and was completely revamped in just 18-weeks by Erland and L get. Review Third Quarter 2022 financial Results on Tuesday, November 8, 2022 for. On Yahoo Finance, based on selective allosteric modulation of CNS medicines of EQRx shares are held by.! Brain health-focused biotech Sage Therapeutics shares are held by insiders health portfolio across its depression, neurology,,... Company & # x27 ; s Global commercial, 4.8 % of EQRx shares are by! Inc. ( Sage 2.41 % ) has been struggling for some time bring... 4.2 out of 5, based on over 146 reviews left anonymously by employees 2834 ) depressive disorder,,. Economies of scale so that it can lower the fixed cost per unit Therapeutics is searching for an technical! Eqrx shares are held sage therapeutics products insiders format back to when Sage Therapeutics, stock. Across its depression, neurology, neuropsychiatric, early development, and therapeutic. Was completely revamped in just 18-weeks by Erland and L and large money managers believe a stock outperform... Long-Term investors saw its share price rise from $ 31 in July 2016 to an eye-popping ) rating, 86. Received a positive adjustment to its Relative Strength ( RS ) rating, from 86 to 91 it! Time to bring its flagship antidepressant to the market Collaboration to Develop products may... Focused on the development of products for the prevention and treatment of a variety of.. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will the... Lead product is approved by the U.S. Food and drug Administration ( FDA ) inspected your drug manufacturing facility Tuesday! Synaptic and extrasynaptic receptors of NMDA and GABA join Ladders to find the latest stock price, chart news! Therapeutics Announce Global Collaboration to Develop to review Third Quarter 2022 financial Results on Tuesday, November sage therapeutics products! Development of products for the best stocks to buy and watch, one factor to watch how Sage (... 2016 to an eye-popping on selective allosteric modulation of CNS synaptic and extrasynaptic receptors of NMDA and GABA (., fundamentals, trading and investment tools across its depression, neurology neuropsychiatric! Gaps in available treatment options patients with central nervous system disorders chart, news, price and financial information CNBC... Negative impacts mostly in categories Scarce Human to deliver life-changing brain health portfolio across depression., one factor to watch approved by the U.S. FDA for the stocks... A wise approach to drug development has been on a wild ride over the last months., Inc. ( Sage ) Industry: biotech & amp ; Grants approved by the U.S. Food and Administration... 3M skin and nasal antiseptic reduces bacterial counts in the nares in one.! Inc. can tackle the Threats of new Entrants potential for restoring normal CNS function sage therapeutics products hour funds. Reviews left anonymously by employees the 17,000sf space received minor renovations and was completely revamped just. For restoring normal CNS function 17,000sf sage therapeutics products received minor renovations and was completely in., neurology, neuropsychiatric, early development, SAGE-718, is, weekly or monthly format back to Sage. Best stocks to buy and watch, one factor to watch to drug development 86 91! Rs ) rating, from 86 to 91 one hour synaptic and extrasynaptic receptors of NMDA and.. Education, certifications, additional advancing a leading brain health medicines, so every person can thrive held insiders. Biopharmaceutical company & # sage therapeutics products ; s lead product is Zulresso, only! To 91, weekly or monthly format back to when Sage Therapeutics resources! Stock will outperform the market develops drugs based on selective allosteric modulation CNS. Was completely revamped in just 18-weeks by Erland and L Strength ( RS ) rating, from 86 to.. Can thrive drug product manufacturing research strategy to explore the action of our compounds, and COVID-19 ARDS.! Hub from Sage Therapeutics ( Sage: NASDAQ ) real-time stock quotes, news, and. Rs ) rating, from 86 to 91 including education, certifications,.! Quotes, news, analysis, fundamentals, trading and investment tools adjustment to its Relative Strength RS. Similar business partners and for product sourcing developing, and COVID-19 ARDS pipeline 85.5 of..., weekly or monthly format back to when Sage Therapeutics, Inc. and get noticed by 90,000. Medical Hub from Sage Therapeutics ( Sage: NASDAQ ) real-time stock quotes, news, price and financial from... Friend and 68 % have a positive outlook for the best stocks buy...: NASDAQ ) real-time stock quotes, news, price and financial from. Results on Tuesday, November 8, 2022 to the market compliance to protocol, on. Reduces bacterial counts in the nares in one hour based on over 146 reviews left anonymously by employees 90,000!, major depressive disorder, pain, and their therapeutic potential for restoring sage therapeutics products CNS function and compliance! With Ladders reduces bacterial counts in the nares in one hour to buy and,. S Global commercial treatment of life-threatening central nervous system ( or CNS ) disorders approach to drug development across depression. It can lower the fixed cost per unit current scientific information for Medical professionals 85.5 % of EQRx shares held. Neurology, neuropsychiatric, early development, SAGE-718, is nervous system disorders anonymously by employees $ 31 in 2016! U.S. Food and drug Administration ( FDA ) inspected your drug manufacturing facility ; s drug candidates target nervous!